21991-39-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one is used as a reactant in the molecular design and synthesis of a series of thiazolidinediones. These compounds are known for their hypoglycemic activity, which helps in improving insulin resistance and managing blood sugar levels in patients with diabetes.
Used in Cardiovascular Applications:
3-Methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one is used as a building block in the development of drugs that target cardiac hypertrophy, a condition characterized by the enlargement of the heart muscles. Its incorporation into pharmaceutical agents can potentially contribute to the prevention or treatment of this condition.
Used in Drug Bioavailability Enhancement:
3-Methyl-1H-imidazo[4,5-b]pyridin-2(3H)-one is utilized in the formulation of drugs to improve their bioavailability. By enhancing the absorption and distribution of the active pharmaceutical ingredients, 3-Methyl-1H-iMidazo[4,5-b]pyridin-2(3H)-one can contribute to the overall effectiveness and therapeutic outcomes of the medications.

Upstream product

• 103432-68-4 1-t-butoxycarbonyl-3-methyl-1,3-dihydro-2H-imidazo<4,5-b>pyridin-2-one 
• 6298-19-7 2-chloro-3-aminopyridine 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 103409-30-9 1-Acetyl-1,3-dihydro-imidazo[4,5-b]pyridin-2-one 
• 452-58-4 2,3-Diaminopyridine 
• 5028-20-6 3-amino-2-methylaminopyridine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 103409-31-0 1-acetyl-3-methyl-1,3-dihydro-2H-imidazo<4,5-b>pyridin-2-one 
• 1281006-64-1 N-benzyl-N-methyl-3-nitropyridin-2-amine 
• 103409-34-3 1,3-di-t-butyloxycarbonyl-1,3-dihydro-2H-imidazo<4,5-b>pyridin-2-one 
• 103409-33-2 1-t-butoxycarbonyl-1,3-dihydro-2H-imidazo<4,5-b>pyridin-2-one 

Downstream Products

• 30458-68-5 2-chloro-3-methyl-3H-imidazo[4,5-b]pyridine 
• 30458-69-6 3-methyl-3H-imidazo[4,5-b]pyridin-2-amine 

Relevant academic research and scientific papers

Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase

In order to explore the interactions of bisphosphonate ligands with the active site and an allosteric pocket of the human farnesyl pyrophosphate synthase (hFPPS), substituted indole and azabenzimidazole bisphosphonates were designed as chameleon ligands. NMR and crystallographic studies revealed that these compounds can occupy both sub-pockets of the active site cavity, as well as the allosteric pocket of hFPPS in the presence of the enzyme's Mg2+ ion cofactor. These results are consistent with the previously proposed hypothesis that the allosteric pocket of hFPPS, located near the active site, plays a feed-back regulatory role for this enzyme.

FUSED HETEROCYCLIC COMPOUNDS

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.

CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS

There are described cydohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists

Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones

A series of imidazopyridine thiazolidine-2,4-diones were designed and synthesized from their corresponding pyridines. These compounds represent conformationally restricted analogues of the novel hypoglycemic compound rosiglitazone (5). The series was evaluated for its effect on insulin-induced 3T3-L1 adipocyte differentiation in vitro and its hypoglycemic activity in the genetically diabetic KK mouse in vivo. The structure-activity relationships are discussed. On the basis of the in vivo potency, 5-[4-(5-methoxy-3-methyl-3H-imidazo[4,5-b]pyridin-2-ylmethoxy)ben zyl]thiazolidine-2,4-dione (19a) was selected as the candidate for further studies in a clinical setting.